Gil M. Labrucherie's Insider Trades & SAST Disclosures
Gil M. Labrucherie's most recent trade in Septerna Inc. was a trade of 6,282 Common Stock done at an average price of $5.6 . Disclosure was reported to the exchange on Feb. 25, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gil M. Labrucherie.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Septerna Inc. | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.59 per share. | 25 Feb 2025 | 6,282 | 36,282 | - | 5.6 | 35,116 | Common Stock |
| Septerna Inc. | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.85 per share. | 25 Feb 2025 | 3,718 | 40,000 | - | 5.8 | 21,750 | Common Stock |
| Septerna Inc. | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.88 per share. | 19 Feb 2025 | 14,500 | 25,000 | - | 5.9 | 85,234 | Common Stock |
| Septerna Inc. | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.51 per share. | 19 Feb 2025 | 10,500 | 10,500 | - | 5.5 | 57,813 | Common Stock |
| Septerna Inc. | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.85 per share. | 19 Feb 2025 | 5,000 | 30,000 | - | 5.9 | 29,250 | Common Stock |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2025 | 25,500 | 25,500 | - | 0 | Common Shares | |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2025 | 15,000 | 15,000 | - | - | Director Stock Option (Right to Buy) | |
| Septerna Inc. | Gil M. Labrucherie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 222,000 | 222,000 | - | - | Stock Option (Right to Buy) | |
| Acelyrin Inc | Gil M. Labrucherie | CFO and CBO | 31 Aug 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | ||
| Acelyrin Inc | Gil M. Labrucherie | CFO and CBO | 23 May 2024 | 184,042 | 184,042 | - | - | Employee Stock Option (right to buy) | ||
| Rezolute Inc | M. Gil Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 30,000 | 30,000 | - | - | Director Stock Option (Right to Buy) | |
| Acelyrin Inc | Gil M. Labrucherie | Chief Financial Officer | 09 Jan 2024 | 855,513 | 855,513 | - | - | Employee Stock Option (right to buy) | ||
| Acelyrin Inc | M. Labrucherie Gil | Chief Financial Officer | 04 Oct 2023 | 40,763 | 40,763 | - | 0 | Common Stock | ||
| Acelyrin Inc | Gil M. Labrucherie | Chief Financial Officer | 17 Aug 2023 | 254,939 | 254,939 | - | - | Employee Stock Option (right to buy) | ||
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 28,750 | 330,353 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 15 May 2022 | 17,448 | 312,905 (0%) | 0% | 4.0 | 68,920 | Common Stock |
| Rezolute Inc | Gil M. Labrucherie | Director | Purchase of securities on an exchange or from another person at price $ 3.80 per share. | 04 May 2022 | 52,631 | 53,572 | - | 3.8 | 199,998 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 16 Feb 2022 | 7,579 | 301,603 (0%) | 0% | 10.9 | 82,990 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 94,000 | 94,000 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 52,950 | 309,182 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 16 Nov 2021 | 21,149 | 259,682 (0%) | 0% | 13.2 | 278,321 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 12.69 per share. | 16 Nov 2021 | 3,000 | 256,682 (0%) | 0% | 12.7 | 38,070 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 71,550 | 71,550 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 16 Aug 2021 | 7,867 | 243,231 (0%) | 0% | 13.8 | 108,801 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.56 per share. | 16 Aug 2021 | 3,000 | 240,231 (0%) | 0% | 13.6 | 40,680 | Common Stock |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 17 May 2021 | 7,898 | 251,098 (0%) | 0% | 18.3 | 144,533 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 22.37 per share. | 16 Feb 2021 | 7,977 | 258,996 (0%) | 0% | 22.4 | 178,445 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 50,000 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 50,000 | 25,000 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 19.81 per share. | 02 Feb 2021 | 50,000 | 266,973 (0%) | 0% | 19.8 | 990,500 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 50,000 | 316,973 (0%) | 0% | 8.8 | 440,000 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 19.61 per share. | 02 Feb 2021 | 50,000 | 266,973 (0%) | 0% | 19.6 | 980,500 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 50,000 | 316,973 (0%) | 0% | 8.8 | 440,000 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 19.97 per share. | 02 Feb 2021 | 41,135 | 275,838 (0%) | 0% | 20.0 | 821,466 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 25,000 | 291,973 (0%) | 0% | 8.8 | 220,000 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 25,000 | 50,000 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 25,000 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 02 Feb 2021 | 25,000 | 316,973 (0%) | 0% | 8.8 | 220,000 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 20.96 per share. | 02 Feb 2021 | 6,932 | 268,906 (0%) | 0% | 21.0 | 145,295 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 21.66 per share. | 02 Feb 2021 | 1,933 | 266,973 (0%) | 0% | 21.7 | 41,869 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 71,500 | 71,500 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 40,000 | 266,973 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 16.93 per share. | 16 Nov 2020 | 8,276 | 226,973 (0%) | 0% | 16.9 | 140,113 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 19.96 per share. | 17 Sep 2020 | 2,000 | 235,249 (0%) | 0% | 20.0 | 39,920 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 19.67 per share. | 17 Aug 2020 | 6,245 | 239,249 (0%) | 0% | 19.7 | 122,839 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 19.68 per share. | 17 Aug 2020 | 2,000 | 237,249 (0%) | 0% | 19.7 | 39,360 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 22.51 per share. | 18 May 2020 | 5,727 | 247,494 (0%) | 0% | 22.5 | 128,915 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 18 May 2020 | 2,000 | 245,494 (0%) | 0% | 22.6 | 45,240 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges